

AVI BIOPHARMA INC  
Form 8-K  
November 05, 2002

---

---

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 5, 2002**

### AVI BioPharma, Inc.

*(Exact name of registrant as specified in its charter)*

**Oregon**  
*(State or other jurisdiction of  
incorporation or organization)*

**0-22613**  
*(Commission File Number)*

**93-0797222**  
*(IRS Employer Identification Number)*

**One S.W. Columbia, Suite 1105  
Portland, OR 97258**  
*(Address of principal executive offices)*

**(503) 227-0554**  
*Registrant's telephone number, including area code*

---

---

#### Item 5. Other Events.

AVI BioPharma, Inc. (the "Company") issued a press release on November 5, 2002, before the opening of trading in its Common Stock on the Nasdaq National Market System, a copy of which is attached as Exhibit 99.

The Press Release announces Third Quarter Financial Results and updates the Company's product research and clinical trials.

#### Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

None

#### SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on November 5, 2002.

AVI BioPharma, Inc.

By: /s/ ALAN P.TIMMINS

---

Alan P. Timmins  
*President and Chief Operating Officer*  
*(Principal Operating Officer)*

2

---